127 related articles for article (PubMed ID: 29456800)
1. Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.
Sammons MF; Kharade SV; Filipski KJ; Boehm M; Smith AC; Shavnya A; Fernando DP; Dowling MS; Carpino PA; Castle NA; Zellmer SG; Antonio BM; Gosset JR; Carlo A; Denton JS
ACS Med Chem Lett; 2018 Feb; 9(2):125-130. PubMed ID: 29456800
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
Tang H; Walsh SP; Yan Y; de Jesus RK; Shahripour A; Teumelsan N; Zhu Y; Ha S; Owens KA; Thomas-Fowlkes BS; Felix JP; Liu J; Kohler M; Priest BT; Bailey T; Brochu R; Alonso-Galicia M; Kaczorowski GJ; Roy S; Yang L; Mills SG; Garcia ML; Pasternak A
ACS Med Chem Lett; 2012 May; 3(5):367-72. PubMed ID: 24900480
[TBL] [Abstract][Full Text] [Related]
3. Discovery of MK-7145, an Oral Small Molecule ROMK Inhibitor for the Treatment of Hypertension and Heart Failure.
Tang H; Zhu Y; Teumelsan N; Walsh SP; Shahripour A; Priest BT; Swensen AM; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Pai LY; Hampton C; Corona A; Hernandez M; Metzger J; Forrest M; Zhou X; Owens K; Tong V; Parmee E; Roy S; Kaczorowski GJ; Yang L; Alonso-Galicia M; Garcia ML; Pasternak A
ACS Med Chem Lett; 2016 Jul; 7(7):697-701. PubMed ID: 27437080
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis.
Garcia ML; Priest BT; Alonso-Galicia M; Zhou X; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Liu J; Swensen A; Pai LY; Xiao J; Hernandez M; Hoagland K; Owens K; Tang H; de Jesus RK; Roy S; Kaczorowski GJ; Pasternak A
J Pharmacol Exp Ther; 2014 Jan; 348(1):153-64. PubMed ID: 24142912
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics.
Aretz CD; Vadukoot AK; Hopkins CR
J Med Chem; 2019 Oct; 62(19):8682-8694. PubMed ID: 31034224
[TBL] [Abstract][Full Text] [Related]
6. The Renal Outer Medullary Potassium Channel (ROMK): An Intriguing Pharmacological Target for an Innovative Class of Diuretic Drugs.
Calderone V; Martelli A; Piragine E; Citi V; Testai L; Breschi MC
Curr Med Chem; 2018; 25(23):2627-2636. PubMed ID: 29022503
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ROMK blocks macula densa tubuloglomerular feedback yet causes renal vasoconstriction in anesthetized rats.
Araujo M; Welch WJ; Zhou X; Sullivan K; Walsh S; Pasternak A; Wilcox CS
Am J Physiol Renal Physiol; 2017 Jun; 312(6):F1120-F1127. PubMed ID: 28228405
[TBL] [Abstract][Full Text] [Related]
8. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.
Richter JM; Gunaga P; Yadav N; Bora RO; Bhide R; Rajugowda N; Govindrajulu K; Godesi S; Akuthota N; Rao P; Sivaraman A; Panda M; Kaspady M; Gupta A; Mathur A; Levesque PC; Gulia J; Dokania M; Ramarao M; Kole P; Chacko S; Lentz KA; Sivaprasad Lvj S; Thatipamula RP; Sridhar S; Kamble S; Govindrajan A; Soleman SI; Gordon DA; Wexler RR; Priestley ES
J Med Chem; 2024 Jun; 67(11):9731-9744. PubMed ID: 38807539
[TBL] [Abstract][Full Text] [Related]
9. Computational and functional analyses of a small-molecule binding site in ROMK.
Swale DR; Sheehan JH; Banerjee S; Husni AS; Nguyen TT; Meiler J; Denton JS
Biophys J; 2015 Mar; 108(5):1094-103. PubMed ID: 25762321
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the renal outer medullary potassium channel: a patent review.
Martelli A; Testai L; Breschi MC; Calderone V
Expert Opin Ther Pat; 2015; 25(9):1035-51. PubMed ID: 26004420
[TBL] [Abstract][Full Text] [Related]
11. Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.
Jiang J; Ding FX; Zhou X; Bateman TJ; Dong S; Gu X; Keh deJesus R; Pio B; Tang H; Chobanian HR; Levorse D; Hu M; Thomas-Fowlkes B; Margulis M; Koehler M; Weinglass A; Gibson J; Houle K; Yudkovitz J; Hampton C; Pai LY; Samuel K; Cutarelli T; Sullivan K; Parmee ER; Davies I; Pasternak A
J Med Chem; 2021 Jun; 64(11):7691-7701. PubMed ID: 34038119
[TBL] [Abstract][Full Text] [Related]
12. ROMK inhibitor actions in the nephron probed with diuretics.
Kharade SV; Flores D; Lindsley CW; Satlin LM; Denton JS
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F732-F737. PubMed ID: 26661652
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of ROMK potency from hERG potency in the phenacetyl piperazine series through heterocycle incorporation.
Walsh SP; Shahripour A; Tang H; de Jesus RK; Teumelsan N; Zhu Y; Frie J; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Ehrhart J; Roy S; Kaczorowski GJ; Yang L; Garcia ML; Pasternak A
Bioorg Med Chem Lett; 2016 May; 26(9):2339-43. PubMed ID: 27017115
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Tang H; de Jesus RK; Walsh SP; Zhu Y; Yan Y; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Roy S; Kaczorowski GJ; Yang L; Garcia ML; Pasternak A
Bioorg Med Chem Lett; 2013 Nov; 23(21):5829-32. PubMed ID: 24075732
[TBL] [Abstract][Full Text] [Related]
15. The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.
Hampton C; Zhou X; Priest BT; Pai LY; Felix JP; Thomas-Fowlkes B; Liu J; Kohler M; Xiao J; Corona A; Price O; Gill C; Shah K; Rasa C; Tong V; Owens K; Ormes J; Tang H; Roy S; Sullivan KA; Metzger JM; Alonso-Galicia M; Kaczorowski GJ; Pasternak A; Garcia ML
J Pharmacol Exp Ther; 2016 Oct; 359(1):194-206. PubMed ID: 27432892
[TBL] [Abstract][Full Text] [Related]
16. Heterozygous disruption of renal outer medullary potassium channel in rats is associated with reduced blood pressure.
Zhou X; Zhang Z; Shin MK; Horwitz SB; Levorse JM; Zhu L; Sharif-Rodriguez W; Streltsov DY; Dajee M; Hernandez M; Pan Y; Urosevic-Price O; Wang L; Forrest G; Szeto D; Zhu Y; Cui Y; Michael B; Balogh LA; Welling PA; Wade JB; Roy S; Sullivan KA
Hypertension; 2013 Aug; 62(2):288-94. PubMed ID: 23753405
[TBL] [Abstract][Full Text] [Related]
17. Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.
Dong S; VanGelder K; Shi ZC; Yu Y; Wu Z; Ferguson R; Guo ZZ; Tang H; Frie J; Fu Q; Gu X; Priest BT; Thomas-Fowlkes B; Weinglass A; Margulis M; Liu J; Pai LY; Hampton C; Haimbach RE; Owens K; Tong V; Xu S; Hu M; Zingaro GJ; Morissette P; Ehrhart J; Roy S; Sullivan K; Pasternak A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2559-2566. PubMed ID: 28431879
[TBL] [Abstract][Full Text] [Related]
18. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease.
Garcia ML; Kaczorowski GJ
Curr Opin Pharmacol; 2014 Apr; 15():1-6. PubMed ID: 24721647
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
